Compare · NTHI vs NVO
NTHI vs NVO
Side-by-side comparison of NeOnc Technologies Holdings Inc. (NTHI) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTHI and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 1568.1x NTHI ($116.8M).
- Over the past year, NTHI is down 36.7% and NVO is down 45.7% - NTHI leads by 9.0 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 3 for NTHI).
- Company
- NeOnc Technologies Holdings Inc.
- Novo Nordisk A/S
- Price
- $4.49-2.18%
- $41.01-4.51%
- Market cap
- $116.8M
- $183.15B
- 1M return
- -32.18%
- -10.44%
- 1Y return
- -36.67%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 8
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NTHI
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- The Next Great AI Revolution May Be Drug Delivery
- NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
- Alliance Global Partners initiated coverage on NeOnc Technologies Holdings with a new price target
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- NeOnc Provides Business Update and Reports Q1 2026 Financial Results
- Maxim Group initiated coverage on NeOnc Technologies Holdings with a new price target
- SEC Form SCHEDULE 13G filed by NeOnc Technologies Holdings Inc.
- SEC Form 10-Q filed by NeOnc Technologies Holdings Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care